This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Winners & Losers: Indevus

Updated from 4:19 p.m. EDT

Health stocks stayed in positive territory overall on Friday with a few regulatory and deal-oriented headlines.

One big mover, Indevus (IDEV), rocketed $1.78, or 103%, to $3.51 on a double dose of positive news.

Indevus said Friday that it will resubmit its application for its testosterone replacement therapy, Nebido, in the first quarter of 2009 and that a new trial -- which could have delayed the filing for up to 18 months -- won't be necessary. Separately, the company announced it will partner with Teva Pharmaceuticals (TEVA) for pagaclone, a drug for treating stuttering that's in midstage development.

Heading in the other direction, NPS Pharmaceuticals (NPSP) said in a filing with the Securities and Exchange Commission on Thursday that GlaxoSmithKline (GSK) is terminating a phase II study of osteoporosis drug Ronacaleret due to lack of efficacy. Shares gave up $1.05, or 12.6%, to $7.28 on Friday.

Also on the decline, Savient Pharmaceuticals' (SVNT - Get Report) shares fell after the company said that it is still evaluating its options for its lead product, pegloticase, as well as other transactions to maximize shareholder value. The company said, however, that it can't give any assurance if or when a deal will get done. The company said it was on track to file its application for the approval of the drug with the FDA by the end of October. Shares declined $2.90, or 15.5%, to $15.82.

In other news, Alpharma (ALO) hasn't tired of rejecting King Pharmaceuticals (KG). The company advised shareholders not to tender their shares to King. Earlier in September, King's board authorized a tender offer to purchase all of the outstanding shares of Class A Common Stock of Alpharma for $37 a share -- up from its initial $33 a share proposal.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SVNT $0.00 0.00%
BMY $65.16 -0.97%
LLY $70.89 -0.96%
NPSP $45.97 0.02%
SNY $52.28 1.02%


DOW 18,037.97 -42.17 -0.23%
S&P 500 2,108.92 -8.77 -0.41%
NASDAQ 5,060.2460 -31.8390 -0.63%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs